Recommendations for the use of tilpotide/tirsiparatide (Mufenda) in special populations

Tirzepatide should be used with extreme caution in special populations, including elderly patients, patients with renal or hepatic impairment, pregnant or lactating women, and those with severe gastrointestinal disease. Since tilpotide has a significant impact on gastric emptying and appetite, elderly patients may be at increased risk of rapid weight loss or insufficient nutritional intake. Therefore, nutritional status and underlying disease conditions should be assessed before use, and weight and blood glucose changes should be closely monitored during treatment.

For patients with renal or hepatic insufficiency, the metabolism and excretion of tilpotide may be affected, and the risk of drug accumulation in the body increases, which may aggravate hypoglycemia or gastrointestinal discomfort. It is recommended that such patients adopt a low-dose starting and gradually increasing regimen, while frequently monitoring blood glucose and liver and kidney function indicators to ensure safety and adjust the dose. For patients with severe renal insufficiency, delaying medication or switching to other blood glucose management strategies may be considered if necessary.

Pregnant and lactating women should use tilpotide with caution. There is currently insufficient clinical data on the long-term effects of this drug on the fetus or infant, so use during pregnancy or breastfeeding is generally not recommended. If treatment must be carried out, the risks and benefits should be weighed under a physician's evaluation and strict monitoring measures should be taken. At the same time, for patients with gastrointestinal diseases, such as chronic gastroparesis or active inflammatory bowel disease, tilpotide may worsen nausea, vomiting, or diarrhea and should be used with caution or considered after symptoms are controlled.

In general, the use of tilpotide in special populations should follow the principle of individualization, with safety as the primary goal. A comprehensive evaluation should be conducted before treatment, and close follow-up should be conducted during treatment, including blood glucose monitoring, weight changes, and liver and kidney function testing. At the same time, patients should maintain good communication with their doctors and promptly report any abnormal reactions so that the dosage can be adjusted or other management measures can be taken to maximize the efficacy and safety of the drug.

Keyword tags: Tilpotide, elderly patients, liver and kidney insufficiency, pregnancy and lactation, individualized medication

Reference:https://en.wikipedia.org/wiki/Tirzepatide